GSK962040 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病4

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004438-32-DE
(EUCTR)
23/10/201313/08/2013The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingA randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 16.1;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040
GlaxoSmithKline Research and Development LimitedNULLNot RecruitingFemale: yes
Male: yes
70Australia;Germany;United Kingdom;Sweden
2EUCTR2011-004438-32-SE
(EUCTR)
26/08/201301/07/2013The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingA randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 16.0;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040
GlaxoSmithKline Research and Development LimitedNULLNot RecruitingFemale: yes
Male: yes
70Australia;Germany;United Kingdom;Sweden
3NCT01602549
(ClinicalTrials.gov)
July 201217/5/2012A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingA Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingGastroparesisDrug: GSK962040 (25 mg tablet);Drug: PlaceboGlaxoSmithKlineNULLCompleted40 Years80 YearsAll58Phase 2Australia;Germany;Sweden;United Kingdom
4EUCTR2011-004438-32-GB
(EUCTR)
25/04/201218/04/2012The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingA randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 20.1;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040
Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040
Product Name: GSK962040
Product Code: GSK962040
INN or Proposed INN: GSK962040
Other descriptive name: GSK962040
GlaxoSmithKline Research and Development LimitedNULLNot Recruiting Female: yes
Male: yes
70 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noGermany;United Kingdom;Sweden